HER2-targeted Therapy Trastuzumab Deruxtecan Shows Early Promise in Patients with Non-breast and Non-gastric Cancers
PHILADELPHIA – A HER2-targeted antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (Enhertu), showed signs of clinical activity in multiple non-breast/non-gastric cancer types,...